- Full analysis of first-in-class CNS-101 study measuring
functional neurophysiology at home in patients living with
mild Alzheimer's dementia
- Poster presentations scheduled for the Technology and
Dementia Preconference on Saturday, July
27th at 8:00 A.M.
EST and main Alzheimer's Association International
Conference (AAIC) Annual Meeting on Tuesday,
July 30th at 8:00 A.M. EST in Philadelphia, Pennsylvania
BELFAST, Northern Ireland and CAMBRIDGE, Mass.,
July 17, 2024 /PRNewswire/ -- Cumulus
Neuroscience (Cumulus; The Company), a global digital health
company focused on advancing neuroscience clinical trials and
patient care through improved data, will present key findings from
their CNS-101 study at the Alzheimer's Association International
Conference 2024 in Philadelphia,
Pennsylvania. The study was conducted in collaboration with
the University of Cambridge.
Two posters were accepted by the AAIC Scientific Program
Committee for presentation at the Technology and Dementia
Preconference and the main meeting. Additionally, one poster
was selected for presentation at the Technology and Dementia
Preconference Data Blitz. Cumulus poster presentation details are
as follows:
Technology and Dementia Preconference
- Title: Technology and Dementia-61 Machine-learning
analysis of real-world multimodal data collected autonomously at
home detects dementia as precisely as a traditional composite
scale
- Session: Technology and Dementia Preconference
Posters
- Date & Time: Saturday, July
27, 2024: 8:00 AM –
3:00 PM EDT
- Poster Number: 94323
- Title: Technology and Dementia-63 A longitudinal
real-world study in patients with Alzheimer's Disease dementia
using frequent multi-domain digital measurements performed at-home
on the Cumulus Neuroassessment Platform: usability and feasibility
findings
- Session: Technology and Dementia Preconference
Posters
- Date & Time: Saturday, July
27, 2024: 8:00 AM –
3:00 PM EST
- Poster Number: 94325
Technology and Dementia Preconference Data
Blitz
- Title: Technology and Dementia-61 Machine-learning
analysis of real-world multimodal data collected autonomously at
home detects dementia as precisely as a traditional composite
scale
- Session: Technology and Dementia Data Blitz
- Date & Time: Saturday July
27, 2024: 11:40 AM –
12:20 PM EDT
- Poster Number: 94323
Alzheimer's Association International Conference
(AAIC)
- Title: Tuesday-315 Machine-learning analysis of
real-world multimodal data collected autonomously at home detects
dementia as precisely as a traditional composite scale
- Date & Time: Tuesday, July
30, 2024: 8:00 AM –
4:15 PM EDT
- Poster Number: 92145
- Session: Biomarkers: Biomarkers (non-neuroimaging)
- Title: Tuesday-316 A longitudinal real-world study in
patients with Alzheimer's Disease dementia using frequent
multi-domain digital measurements performed at-home on the Cumulus
Neuroassessment Platform: usability and feasibility findings
- Date & Time: Tuesday, July
30, 2024: 8:00 AM –
4:15 PM EDT
- Poster Number: 92164
- Session: Biomarkers: Biomarkers (non-neuroimaging)
"Traditional measures used in Alzheimer's clinical studies lack
objectivity, do not scale to support large real-world studies, and
require patients to attend clinic appointments which can be highly
stressful, impacting results," said Brian Murphy, PhD, Founder
and Chief Scientific Officer of Cumulus. "Importantly, these
measures do not provide a clear picture regarding neurological
health in a patient's day-to-day life. We need scalable digital
biomarkers that enable objective, longitudinal measurement of brain
function in a real-world setting. We look forward to sharing
results from our CNS-101 study at AAIC 2024. We are deeply grateful
to all the study participants and collaborators who have dedicated
their careers to better understanding this devastating
neurodegenerative disease with the hope of accelerating the
development of much needed therapies."
Alzheimer's is a progressive disease that affects brain
function, memory, and other cognitive abilities. It is the most
common cause of dementia, affecting millions of people worldwide.
Symptoms usually develop slowly and worsen over time, including
memory loss, confusion, difficulty with language and communication,
mood swings, and changes in behavior and personality. Currently,
there is no known cure for Alzheimer's.
Cumulus supports precision in CNS clinical trials for its
industry partners by enabling remote monitoring of patients across
multiple domains of brain function. To learn more,
visit www.cumulusneuro.com.
About Cumulus Neuroscience
With a mission to generate
the data and insights required to accelerate diagnosis and
management of central nervous system (CNS) disorders for millions
of patients and caregivers around the world, Cumulus Neuroscience
is advancing NeuLogiq™, an AI-based, multi-domain
digital biomarker platform to enable better, faster decision making
in neurology and neuropsychiatry clinical trials and patient care.
Designed for and with 10 of the world's leading pharma companies,
the platform enables decentralized trials, and is already making a
difference in the development of therapies for Alzheimer's Disease,
depression and schizophrenia.
Designed to provide an industry-wide standard for real-world
measurement of disease progression, Cumulus combines patented
technology, in-house expertise and key industry partnerships to
capture large amounts of real-world, clinical data repeated over
time, across multiple behavioral and physiological domains in the
patient's home – all with an EEG headset synced to a novel,
tablet-based neuro-assessment platform. Together with machine
learning (ML) analytics and the world's largest database of
annotated, longitudinal, neurofunctional data, Cumulus simplifies
and improves the robustness of neuroscience clinical trials to
provide the best and most cost-effective assessment of CNS
treatment outcomes.
The Company is supported by highly experienced specialized
investors, DDF/SV Health Investors, LifeArc and Future Fund, and a
world-class Scientific and Technical Advisory Board.
FOR MORE INFORMATION
Julie
Dietel
FINN Partners for Cumulus
julie.dietel@finnpartners.com
Tel: 978.502.7705
Logo -
https://mma.prnewswire.com/media/1903807/Cumulus_Neuroscience_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/cumulus-neuroscience-to-present-data-at-aaic-2024-annual-meeting-and-technology-and-dementia-preconference-302198739.html